Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.

doi:10.2217/pgs-2022-0023

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.

Pharmacogenomics - 1 Jul 2022

Herrero Rivera Daniel, Vacas Carmen Garrigós, Kovandzic Laura Marcos, Vázquez Javier Puente, Alonso Lucía A, González Begoña Mellado, Aragón Verónica Calderero, Grande Enrique, Caro Raquel Luque, Virizuela Echaburu Juan A, Rodríguez Moreno Juan F, Etxebarria Ainara A, Rodríguez-Antona Cristina, Durán Ignacio

Abstract excerpt

Background: The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: 56 SNPs in five genes (CYP3A4, CYP3A5, ABCB1, TUBB1 and CYP2C8) were genotyped in 67 mCRPC patients and their correlation with outcomes analyzed. Results:TUBB1-rs151352...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to ATP Binding Cassette Transporter, Subfamily B

Share to Cytochrome P-450 CYP2C8

Share to Cytochrome P-450 CYP3A

Share to Prostatic Neoplasms, Castration-Resistant

Share to Taxoids

Share to Treatment Outcome

Share to Tubulin

Source

Open in PubMed

Identifiers

PMID: 35880554
DOI: 10.2217/pgs-2022-0023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.PMID 35880554Read ↗

The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.Semantic proximity Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.Semantic proximity Read ↗

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.Semantic proximity Read ↗

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.Semantic proximity Read ↗

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Semantic proximity Read ↗

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.Semantic proximity Read ↗

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.Semantic proximity Read ↗

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.Semantic proximity Read ↗

YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.